Navigation Links
Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection
Date:4/11/2008

(average CMI = 438 ng/mL ATP) than the average measure among patients showing no signs of rejection (average CMI = 301 ng/mL ATP; p = 0.05).

The analysis also looked at the incidence of infections among the study population. A total of 30 infections were identified in patients with low CMI (<225 ng/mL ATP; based on 57 assays) as compared to only eight infections in patients with moderate or strong CMI (>225 ng/mL ATP; based on 113 assays). The average CMI in samples from patients with infection was 119 ng/mL ATP as compared to 336 ng/mL ATP in samples from patients with no sign of infection (p < 0.001). Identified infections included 13 with a viral etiology; 15 with bacterial etiology; and 10 with fungal etiology.

"Immune function monitoring of adult heart transplant patients using the ImmuKnow assay may have the potential to aid in the assessment of the immune status of the patient and the patient's risk for organ rejection or infection," concluded Dr. Kobashigawa. "We are currently conducting clinical studies using these data to manage immunosuppression in our heart transplant patients, with the goal of limiting risk for rejection and infection."

Dr. Kobashigawa's presentation was entitled, "Success of immune monitoring with ImmuKnow (Cylex(TM)) to assess rejection/infectious risk in heart transplantation." Dr. Kobashigawa is Clinical Professor of Medicine and Chief of the Division of Clinical Faculty Medicine at David Geffen School of Medicine at UCLA. He is also Medical Director of the UCLA Heart Transplant Program.

About ImmuKnow(R)

ImmuKnow is an immune cell function assay that can detect cell-mediated immunity (CMI) in adult immunosuppressed patients by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunc
'/>"/>

SOURCE Cylex Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
2. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Seneca Valley High School Student Receives Science Award From MedImmune
5. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
8. Immune system protein starves staph bacteria
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. MedImmune Submits Biologics License Application to FDA for Motavizumab
11. Peptimmune Announces First Close of Series D Private Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Southern Illinois University Edwardsville ... of vice president of instruction at Chippewa Valley Technical College (CVTC) and will ... opportunity to lead SIUE during the past three years,” Furst-Bowe said. “I want ...
(Date:6/29/2015)... ... June 29, 2015 , ... MediVet Biologics today announced ... agreement, MediVet will acquire the rights to a portfolio of cultures, products and ... development as a potential next-generation treatment for various musculoskeletal and internal medicine conditions ...
(Date:6/29/2015)... Md. , June 29, 2015  Neuralstem, Inc. ... cell technology to develop small molecule and cell therapy ... it has been approved for listing on the NASDAQ ... stock will continue to trade on the NYSE MKT ... on the NASDAQ Capital Market is expected to commence ...
(Date:6/29/2015)... -- Elsevier , a world-leading provider ... today announced the highlights of its journal Impact Factor ... Reports® (JCR) published by Thomson Reuters, Elsevier saw 55% ... 2014, ahead of the aggregate across other journals. In ... subject categories, up from 61 in 2013. ...
Breaking Biology Technology:SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3
... tracking the number and dimension of particles or droplets as they ... are specific and possibly unique, changes that are of critical importance ... provide you with the knowledge, information and best practices you need ... ...
... of a new system to study crystallization processes for ... name,Crystalline. , The Crystalline has ... to learn as much as possible about a drug ... "Avantium is proud to launch its next system ...
... Institute have discovered a new method for controlling ... potentially one step closer to realizing the mass ... sheet of carbon, was discovered in 2004 and ... silicon as the fundamental building blocks of nanoelectronics. ...
Cached Biology Technology:Maximize Data Analysis with METTLER TOLEDO FBRM 2Avantium Launches the Crystalline, a New Parallel System for Crystallization Research 2Light-speed nanotech: Controlling the nature of graphene 2
(Date:6/24/2015)... , June 22, 2015 ... the addition of the "Huawei Ascend Mate ... report to their offering. Huawei,s technological ... the opposite direction than Apple,s and Samsung,s one. ... sensor developed by Fingerprint Cards, a main actor ...
(Date:6/23/2015)... 23, 2015   MedNet Solutions , an ... entire spectrum of clinical research, is pleased to ... , the company,s intuitive, flexible and affordable cloud-based ... 2015 Stevie® Award by the American Business ... Website category.  The American Business Awards are considered ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... announced the results of a recent study that ... on the wrist during activity. In a study ... was compared along with the Apple Watch against ... measuring heart rate during activity. The study demonstrated ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... vast majority of patients who had a successful ... need mitral valve surgery three years after their ... of the left ventricle (commonly known as reverse ... the Cardiovascular Research Foundations (CRF) nineteenth annual Transcatheter ...
... D.C. October 24, 2007 - The U.S. Senate ... Appropriations Bill (S.1710), including a provision that directs the ... Access Policy by requiring rather than requesting participation by ... House Appropriations Bill, which contains a similar provision, in ...
... Germany-October 24, 2007-Harvard University,s Office of Technology Development ... jointly establish the BASF Advanced Research Initiative. ... and Applied Sciences (SEAS) the initiative will benefit ... throughout the University. Set up as a ...
Cached Biology News:New data shows benefits of MitraClip for patients with mitral regurgitation 2New data shows benefits of MitraClip for patients with mitral regurgitation 3Mandate for public access to NIH-funded research poised to become law 2BASF and Harvard University announce extensive research collaboration 2
Synaptic Vesicle I Sampler Kit 10g each...
Mouse monoclonal [3A7.A11] to Thymidylate Synthase ( Abpromise for all tested applications). entrezGeneID: 7298 SwissProtID: P04818...
Mouse monoclonal [N7519] to NR0B2 ( Abpromise for all tested applications). Antigen: E.coli expressed recombinant full length protein (Human) NR0B2 Entrez Gene ID: 8431 Swiss Protein ID: ...
Integrins Sampler Kit 10g each...
Biology Products: